Natasha Fay Thoren - 20 May 2025 Form 3 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Legal Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
20 May 2025
Net transactions value
$0
Form type
3
Filing time
03 Jun 2025, 18:12:48 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thoren Natasha Fay Chief Legal Officer C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON /s/ Adam S. Mostafa, attorney-in-fact 03 Jun 2025 0002070977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XFOR Common Stock 6,984 20 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XFOR Stock Option (right to buy) 20 May 2025 Common Stock 8,166 $32.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 2,818 shares of common stock and (ii) 4,166 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock on the applicable vesting date. The RSUs vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide services through each such date.
F2 25% of the shares subject to the option vested on September 5, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.

Remarks:

Exhibit List: Exhibit 24 Power of Attorney